Találati lista | Tudóstér

001-es BibID:	BIBFORM036662
Első szerző:	Elmazar, Mohamed M. A.
Cím:	Synergistic teratogenic effects induced by retinoids in mice by coadministration of a RARalpha- or RARgamma-selective agonist with a RXR-selective agonist / Elmazar M. M., Rühl R., Nau H.
Dátum:	2001
ISSN:	0041-008X
Megjegyzések:	To study the interaction of retinoid-induced limb defects and cleft palate on day 11 of gestation, a RXR-selective agonist (AGN191701, an arylpropenyl-thiophene-carboxylic acid derivative, 20 mg/kg orally) was coadministered with a RARalpha-agonist (Am580, an arylcarboxamidobenzoic acid derivative, 5 mg/kg orally) to NMRI mice. AGN191701 was neither fetotoxic nor teratogenic at the dose used but potentiated Am580-induced limb defects and cleft palate and prevented Am580-induced fetal weight retardation. These results suggest that Am580-induced limb defects and probably cleft palate on day 11 of gestation may be mediated via RARalpha-RXR heterodimerization, particularly in the absence of toxicokinetic interactions. AGN191701 was also coadministered with a RARgamma-agonist (CD437, an adamantyl-hydroxyphenyl naphthoic acid derivative, 15 mg/kg orally) on days 8 and 11 of gestation to investigate which CD437-induced defects are mediated via RARgamma-RXR heterodimerization. On day 8 of gestation, AGN191701 potentiated CD437-induced embryolethality, exencephaly, spina bifida aperta, cleft palate, and tail defects, as well as visceral and skeletal defects, but not micrognathia. On day 11 of gestation, the incidence of CD437-induced cleft palate and limb defects was also potentiated when coadministered with the RXR agonist. These results suggest that synergistic teratogenic effects can be induced by coadministration of two receptor-selective retinoids, indicating the importance of RARalpha-RXR and RARgamma-RXR heterodimers in producing structural defects during organogenesis.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Toxicology And Applied Pharmacology. - 170 : 1 (2001), p. 2-9. -
További szerzők:	Rühl, Ralph (1969-) (vegyész) Nau, Heinz
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM042927
035-os BibID:	PMID:23466426
Első szerző:	Palicz Zoltán (orvos)
Cím:	In vivo application of a small molecular weight antifungal protein of Penicillium chrysogenum (PAF) / Zoltán Palicz, Ágnes Jenes, Tamás Gáll, Kornél Miszti-Blasius, Sándor Kollár, Ilona Kovács, Miklós Emri, Teréz Márián, Éva Leiter, István Pócsi, Éva Csősz, Gergő Kalló, Csaba Hegedűs, László Virág, László Csernoch, Péter Szentesi
Dátum:	2013
ISSN:	0041-008X
Megjegyzések:	The antifungal protein of Penicillium chrysogenum (PAF) inhibits the growth of important pathogenic filamentous fungi, including members of the Aspergillus family and some dermatophytes. Furthermore, PAF was proven to have no toxic effects on mammalian cells in vitro. To prove that PAF could be safely used in therapy, experiments were carried out to investigate its in vivo effects. Adult mice were inoculated with PAF intranasally in different concentrations, up to 2700g·kg(-1) daily, for 2weeks. Even at the highest concentration - a concentration highly toxic in vitro for all affected molds - used, animals neither died due to the treatment nor were any side effects observed. Histological examinations did not find pathological reactions in the liver, in the kidney, and in the lungs. Mass spectrometry confirmed that a measurable amount of PAF was accumulated in the lungs after the treatment. Lung tissue extracts from PAF treated mice exerted significant antifungal activity. Small-animal positron emission tomography revealed that neither the application of physiological saline nor that of PAF induced any inflammation while the positive control lipopolysaccharide did. The effect of the drug on the skin was examined in an irritative dermatitis model where the change in the thickness of the ears following PAF application was found to be the same as in control and significantly less than when treated with phorbol-12-myristate-13-acetate used as positive control. Since no toxic effects of PAF were found in intranasal application, our result is the first step for introducing PAF as potential antifungal drug in therapy.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Molekuláris Medicina
Megjelenés:	Toxicology and Applied Pharmacology 269 : 1 (2013), p. 8-16. -
További szerzők:	Jenes Ágnes (1980-) (élettanász) Gáll Tamás (1982-) (molekuláris biológus, mikrobiológus) Miszti-Blasius Kornél (1977-) (laboratóriumi szakorvos) Kollár Sándor (1949-) (sebész) Kovács Ilona (1965-) (patológus) Emri Miklós (1962-) (fizikus) Márián Teréz (1950-) (radiobiológus) Leiter Éva (1976-) (biológus) Pócsi István (1961-) (vegyész) Csősz Éva (1977-) (biokémikus, molekuláris biológus) Kalló Gergő (1989-) (molekuláris biológus) Hegedűs Csaba (1980-) (biokémikus, molekuláris biológus) Virág László (1965-) (biokémikus, sejtbiológus, farmakológus) Csernoch László (1961-) (élettanász) Szentesi Péter (1967-) (élettanász)
Pályázati támogatás:	TÁMOP-4.2.1/B-09/1/KONV-2010-0007 TÁMOP Oxidatív stressz és ADP-riboziláció kapcsolatának vizsgálata TÁMOP-4.2.2/B-10/1-2010-0024 TÁMOP Molekuláris Orvostudomány Doktori Iskola TÁMOP-4.2.2.A-11/1/KONV-2012-0025 TÁMOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: